Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients - PubMed (original) (raw)
. 2010 Dec;56(12):1814-21.
doi: 10.1373/clinchem.2010.146506. Epub 2010 Oct 4.
Affiliations
- PMID: 20921266
- DOI: 10.1373/clinchem.2010.146506
Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients
James L Januzzi Jr et al. Clin Chem. 2010 Dec.
Abstract
Background: Although numerous biomarkers may be prognostically meaningful in patients with acute dyspnea, few comparative analyses have addressed possible associations between a wide range of candidate biomarkers and clinical variables.
Methods: Vital status was obtained for 517 acutely dyspneic patients at 4 years after emergency department presentation. A wide array of biomarkers was measured in this cohort, including natriuretic peptides, necrosis markers, inflammatory markers, hematologic markers, and renal markers. We performed statistical evaluation by using minimization of the Bayesian information criterion to evaluate predictors of 4-year mortality. Cox proportional hazards analysis was used to confirm results from the Bayesian information criterion. A final risk model was derived, and this model was then validated by applying it to patients from a separate cohort of acutely dyspneic patients.
Results: By 4 years, there were 186 deaths (36%). In addition to several clinical variables, several biomarkers were significant predictors of death, including log-transformed concentrations of hemoglobin (hazard ratio=0.77; P < 0.001), soluble ST2 (hazard ratio=1.38; P < 0.001), and amino-terminal pro-B-type natriuretic peptide (hazard ratio=1.19; P < 0.001). Risk models that used these significant variables were accurate in predicting 4-year mortality in both the training and validation sets.
Conclusions: When added to traditional clinical variables, selected biomarkers added significant value for long-term prognostication in acute dyspnea.
Similar articles
- Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.
Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Januzzi JL Jr, et al. J Am Coll Cardiol. 2007 Aug 14;50(7):607-13. doi: 10.1016/j.jacc.2007.05.014. Epub 2007 Jul 30. J Am Coll Cardiol. 2007. PMID: 17692745 - Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.
Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Shah RV, et al. Circ Heart Fail. 2009 Jul;2(4):311-9. doi: 10.1161/CIRCHEARTFAILURE.108.833707. Epub 2009 May 14. Circ Heart Fail. 2009. PMID: 19808354 - Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction.
Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, Hanson K, Li SY, deFilippi CR. Shah KB, et al. Clin Chem. 2011 Jun;57(6):874-82. doi: 10.1373/clinchem.2010.159277. Epub 2011 Apr 22. Clin Chem. 2011. PMID: 21515743 - Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure.
Baggish AL, van Kimmenade RR, Januzzi JL Jr. Baggish AL, et al. Am J Cardiol. 2008 Feb 4;101(3A):49-55. doi: 10.1016/j.amjcard.2007.11.020. Am J Cardiol. 2008. PMID: 18243859 Review. - Role of biomarkers in patients with dyspnea.
Gori CS, Magrini L, Travaglino F, Di Somma S. Gori CS, et al. Eur Rev Med Pharmacol Sci. 2011 Feb;15(2):229-40. Eur Rev Med Pharmacol Sci. 2011. PMID: 21434492 Review.
Cited by
- Multi-Marker Approach in Patients with Acute Chest Pain in the Emergency Department.
Piccioni A, Baroni S, Manca F, Sarlo F, Savioli G, Candelli M, Bronzino A, Covino M, Gasbarrini A, Franceschi F. Piccioni A, et al. J Pers Med. 2024 May 25;14(6):564. doi: 10.3390/jpm14060564. J Pers Med. 2024. PMID: 38929785 Free PMC article. - Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping.
Dong X, Xie Y, Xu J, Qin Y, Zheng Q, Hu R, Zhang X, Wang W, Tian J, Yi K. Dong X, et al. Heliyon. 2023 Feb 7;9(2):e13509. doi: 10.1016/j.heliyon.2023.e13509. eCollection 2023 Feb. Heliyon. 2023. PMID: 36825183 Free PMC article. - Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.
Kott KA, Bishop M, Yang CHJ, Plasto TM, Cheng DC, Kaplan AI, Cullen L, Celermajer DS, Meikle PJ, Vernon ST, Figtree GA. Kott KA, et al. Cells. 2022 Feb 8;11(3):588. doi: 10.3390/cells11030588. Cells. 2022. PMID: 35159397 Free PMC article. Review. - Biological markers and cardiac remodelling following the myocardial infarction.
Gruzdeva O, Dyleva Y, Uchasova E, Akbasheva O, Karetnikova V, Kashtalap V, Shilov A, Polikutina O, Slepynina Y, Barbarash O. Gruzdeva O, et al. Aging (Albany NY). 2019 Jun 10;11(11):3523-3535. doi: 10.18632/aging.101994. Aging (Albany NY). 2019. PMID: 31182683 Free PMC article. - Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure.
Matsumoto H, Kasai T, Sato A, Ishiwata S, Yatsu S, Shitara J, Murata A, Kato T, Suda S, Matsue Y, Hiki M, Takagi A, Daida H. Matsumoto H, et al. Heart Vessels. 2019 Dec;34(12):1961-1968. doi: 10.1007/s00380-019-01435-9. Epub 2019 May 18. Heart Vessels. 2019. PMID: 31104078
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical